Does the media favor AMN or OMCL?

In the previous week, AMN Healthcare Services had 5 more articles in the media than Omnicell. MarketBeat recorded 9 mentions for AMN Healthcare Services and 4 mentions for Omnicell. AMN Healthcare Services' average media sentiment score of 0.33 beat Omnicell's score of 0.22 indicating that AMN Healthcare Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OMCL or WST?

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Omnicell. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 4 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 0.78 beat Omnicell's score of 0.22 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral West Pharmaceutical Services 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, OMCL or HSTM?

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.23B 1.77 $2.05M $0.44 108.35 HealthStream $311.78M 2.70 $18.34M $0.67 43.00

Do analysts rate OMCL or MDRX?

Omnicell presently has a consensus target price of $59.86, suggesting a potential upside of 25.55%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.23B 1.77 $2.05M $0.44 108.35 Veradigm $1.53B 0.41 N/A N/A N/A

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Veradigm N/A N/A N/A

Which has better earnings and valuation, HNGE or OMCL?

Omnicell has higher revenue and earnings than Hinge Health. Hinge Health is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86M 11.60 -$528.26M -$12.34 N/A Omnicell $1.23B 1.77 $2.05M $0.44 108.35

Is HNGE or OMCL more profitable?

Omnicell has a net margin of 1.67% compared to Hinge Health's net margin of -78.95%. Omnicell's return on equity of 4.00% beat Hinge Health's return on equity. Company Net Margins Return on Equity Return on Assets Hinge Health -78.95% -310.62% -71.08% Omnicell 1.67% 4.00% 2.46%

Does the media refer more to HNGE or OMCL?

In the previous week, Hinge Health had 10 more articles in the media than Omnicell. MarketBeat recorded 14 mentions for Hinge Health and 4 mentions for Omnicell. Hinge Health's average media sentiment score of 0.80 beat Omnicell's score of 0.22 indicating that Hinge Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Omnicell (OMCL) Competitors

$47.68 +0.86 (+1.83%)

As of 11:30 AM Eastern

Compare

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), Veradigm (MDRX), and Hinge Health (HNGE).

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$3.42B	0.39	-$95.70M	-$0.87	N/A
Omnicell	$1.23B	1.77	$2.05M	$0.44	108.35

AMN Healthcare Services presently has a consensus price target of $27.00, suggesting a potential downside of 21.75%. Omnicell has a consensus price target of $59.86, suggesting a potential upside of 25.55%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, AMN Healthcare Services had 5 more articles in the media than Omnicell. MarketBeat recorded 9 mentions for AMN Healthcare Services and 4 mentions for Omnicell. AMN Healthcare Services' average media sentiment score of 0.33 beat Omnicell's score of 0.22 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Omnicell	1.67%	4.00%	2.46%

AMN Healthcare Services has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 10 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

Omnicell (NASDAQ:OMCL) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
West Pharmaceutical Services	16.85%	19.03%	14.06%

Omnicell currently has a consensus target price of $59.86, indicating a potential upside of 25.55%. West Pharmaceutical Services has a consensus target price of $363.17, indicating a potential upside of 0.13%. Given Omnicell's higher possible upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.23B	1.77	$2.05M	$0.44	108.35
West Pharmaceutical Services	$3.22B	7.96	$493.70M	$7.48	48.49

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Omnicell. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 4 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 0.78 beat Omnicell's score of 0.22 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
West Pharmaceutical Services	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

West Pharmaceutical Services beats Omnicell on 13 of the 17 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both health care technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
HealthStream	6.39%	6.47%	4.44%

Omnicell has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 25.55%. HealthStream has a consensus price target of $24.00, suggesting a potential downside of 16.70%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts plainly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.23B	1.77	$2.05M	$0.44	108.35
HealthStream	$311.78M	2.70	$18.34M	$0.67	43.00

In the previous week, Omnicell had 3 more articles in the media than HealthStream. MarketBeat recorded 4 mentions for Omnicell and 1 mentions for HealthStream. HealthStream's average media sentiment score of 1.44 beat Omnicell's score of 0.22 indicating that HealthStream is being referred to more favorably in the news media.

Company	Overall Sentiment
Omnicell	Neutral
HealthStream	Positive

97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Omnicell and HealthStream tied by winning 8 of the 16 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both health care technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.23B	1.77	$2.05M	$0.44	108.35
Veradigm	$1.53B	0.41	N/A	N/A	N/A

Omnicell has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Omnicell presently has a consensus target price of $59.86, suggesting a potential upside of 25.55%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Omnicell had 4 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Omnicell and 0 mentions for Veradigm. Omnicell's average media sentiment score of 0.22 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Neutral
Veradigm	Neutral

97.7% of Omnicell shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Omnicell compare to Hinge Health?

Hinge Health (NYSE:HNGE) and Omnicell (NASDAQ:OMCL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Hinge Health currently has a consensus target price of $82.67, suggesting a potential downside of 6.19%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 25.55%. Given Omnicell's higher probable upside, analysts clearly believe Omnicell is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.95
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Omnicell has higher revenue and earnings than Hinge Health. Hinge Health is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$587.86M	11.60	-$528.26M	-$12.34	N/A
Omnicell	$1.23B	1.77	$2.05M	$0.44	108.35

In the previous week, Hinge Health had 10 more articles in the media than Omnicell. MarketBeat recorded 14 mentions for Hinge Health and 4 mentions for Omnicell. Hinge Health's average media sentiment score of 0.80 beat Omnicell's score of 0.22 indicating that Hinge Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.7% of Omnicell shares are owned by institutional investors. 18.9% of Hinge Health shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hinge Health has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Omnicell has a net margin of 1.67% compared to Hinge Health's net margin of -78.95%. Omnicell's return on equity of 4.00% beat Hinge Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	-78.95%	-310.62%	-71.08%
Omnicell	1.67%	4.00%	2.46%

Summary

Omnicell beats Hinge Health on 9 of the 17 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.17B	$1.85B	$6.88B	$12.57B
Dividend Yield	N/A	N/A	2.68%	9.45%
P/E Ratio	108.29	77.48	27.24	24.31
Price / Sales	1.77	27.45	509.95	88.89
Price / Cash	16.61	27.64	48.63	60.00
Price / Book	1.74	5.60	10.95	6.28
Net Income	$2.05M	-$54.76M	$3.59B	$331.55M
7 Day Performance	4.57%	-1.71%	-1.90%	-1.36%
1 Month Performance	19.49%	4.25%	3.54%	-0.43%
1 Year Performance	71.62%	0.09%	26.74%	19.22%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.5666 of 5 stars	$47.68 +1.8%	$59.86 +25.6%	+71.9%	$2.17B	$1.23B	108.29	3,580
AMN AMN Healthcare Services	1.6333 of 5 stars	$35.84 +3.1%	$27.00 -24.7%	+62.9%	$1.35B	$2.73B	N/A	2,664	Positive News Analyst Revision
WST West Pharmaceutical Services	2.896 of 5 stars	$357.73 -2.2%	$351.91 -1.6%	+62.4%	$25.84B	$3.07B	47.82	10,800	Upcoming Earnings Analyst Forecast
HSTM HealthStream	2.4957 of 5 stars	$29.07 +2.3%	$24.00 -17.4%	+5.8%	$830M	$304.06M	43.39	1,160	Positive News
MDRX Veradigm	N/A	$4.65 -8.7%	N/A	-4.0%	$568.70M	$1.53B	23.25	8,000	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

How does Omnicell compare to Hinge Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HNGE

How does Omnicell compare to AMN Healthcare Services?

Do institutionals and insiders have more ownership in AMN or OMCL?

Which has stronger valuation & earnings, AMN or OMCL?

Do analysts recommend AMN or OMCL?

Does the media favor AMN or OMCL?

Is AMN or OMCL more profitable?

Which has more risk and volatility, AMN or OMCL?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Is OMCL or WST more profitable?

Do analysts recommend OMCL or WST?

Do institutionals and insiders believe in OMCL or WST?

Which has more risk and volatility, OMCL or WST?

Which has stronger earnings and valuation, OMCL or WST?

Does the media favor OMCL or WST?

Summary

How does Omnicell compare to HealthStream?

Is OMCL or HSTM more profitable?

Which has more risk & volatility, OMCL or HSTM?

Do analysts recommend OMCL or HSTM?

Which has higher valuation & earnings, OMCL or HSTM?

Does the media refer more to OMCL or HSTM?

Do insiders & institutionals hold more shares of OMCL or HSTM?

Summary

How does Omnicell compare to Veradigm?

Which has higher earnings & valuation, OMCL or MDRX?

Which has more risk & volatility, OMCL or MDRX?

Do analysts rate OMCL or MDRX?

Does the media favor OMCL or MDRX?

Do insiders and institutionals hold more shares of OMCL or MDRX?

Is OMCL or MDRX more profitable?

Summary

How does Omnicell compare to Hinge Health?

Do analysts recommend HNGE or OMCL?

Which has better earnings and valuation, HNGE or OMCL?

Does the media refer more to HNGE or OMCL?

Do insiders & institutionals have more ownership in HNGE or OMCL?

Which has more volatility and risk, HNGE or OMCL?

Is HNGE or OMCL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools